News
FDA Approves Wegovy to Treat Serious Liver Disease
The approval makes Wegovy the only GLP-1 therapy cleared to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis. About 14.9 million U.S. adults — or roughly 6% of the population — have the condition, according to the FDA.
Novo's Wegovy picks up 3rd indication with key FDA approval in the liver disease MASH
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. | The FDA has signed off on an accelerated approval for Novo Nordisk's Wegovy to treat certain adults with metabolic-associated steatohepatitis.
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.
GoodRx will offer the GLP-1s for $499 a month, the lowest-ever out-of-pocket cost for the weight-loss medications.
While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...
In a significant development for weight management, the Food and Drug Administration (FDA) announced Wednesday its approval ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback